In connection with the Company's rights issue of units, which was resolved on at the extraordinary general meeting on June 8, 2023, CLS issued 234,582,810 warrants of series TO 6 B.

Each warrant of series TO 6 B entitles the holder to subscribe for one (1) new B-share in CLS during the exercise period that runs from January 23, 2024, until February 6, 2024. The subscription price for warrants of series TO 6 B has been set at SEK 0.10 per share, which corresponds to seventy (70) percent of the average volume-weighted price of the B-share according to Nasdaq First North Growth Market's official price statistics during the period from and including January 8, 2024, to and including January 19, 2024, rounded to the nearest whole Swedish öre. At full subscription of warrants of series TO 6 B, the Company will be provided proceeds of approximately SEK 23.5 million before deduction of transaction related costs.

Upon full exercise of warrants of series TO 6 B, the number of shares in CLS will increase by 234,582,810 B-shares to a total of 1,570,341,299 shares (of which 600,000 A-shares) and the share capital will increase by approximately SEK 2,708,939.05 to approximately SEK 18,134,145.72. The dilution at full subscription amounts to approximately 14.94 percent of the capital and 14.89 percent of the votes.

Complete terms and conditions for warrants of series TO 6 B are available on the Company's website (www.clinicallaser.se). An information brochure containing summary information about the Company and the warrant exercise will be available on the websites of CLS, Sedermera Corporate Finance AB's, Redeye AB's and Nordic Issuing AB's respective websites (www.clinicallaser.se, www.sedermera.se, www.redeye.se, www.nordic-issuing.se).

• January 23, 2024: The exercise period begins
• February 2, 2024: Last day of trading in warrants
• February 6, 2024: The exercise period ends
• February 6-8, 2024: Planned communication of the outcome of the warrant exercise
• February 27, 2024: Date of estimated conversion of interim shares to B-shares

Advisors

In connection with the exercise of warrants of series TO 6 B, Sedermera Corporate Finance AB and Redeye AB are Joint Lead Managers. Markets & Corporate Law Nordic AB is legal advisor and Nordic Issuing AB acts as issuing agent.

For more information about the warrants of series TO 6 B, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: info@sedermera.se

Website: www.sedermera.se

Redeye AB

Phone: +46 (0)8 545 013 30

E-mail: info@redeye.se

Website: www.redeye.se

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: clinicallaser.se (http://file:///C:\Users\anna.spangs\Workplace\Paues%20Åberg\Kunder\Clinial%20Laserthermia%20Systems\clinicallaser.se)